Loading...
XNASBCLI
Market cap12mUSD
Dec 31, Last price  
2.27USD
1D
-4.22%
1Q
-14.02%
Jan 2017
-94.04%
Name

Brainstorm Cell Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:BCLI chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.59%
Rev. gr., 5y
%
Revenues
0k
000000000000000-366,0000000
Net income
-17m
L-27.56%
-73,295-18,839,795-3,924,485-6,244,000-3,472,000-1,781,000-2,419,000-3,918,000-3,430,000-4,899,000-9,246,000-8,488,000-4,982,000-4,952,000-13,833,000-23,505,000-31,938,000-24,375,000-23,732,000-17,192,000
CFO
-20m
L+5.89%
-15,436-677,836-854,643-1,774,000-1,734,000-744,000-2,069,000-2,223,000-2,916,000-4,054,000-4,487,000-7,408,000-5,858,000-2,364,000-12,388,000-11,247,000-35,193,000-26,265,000-19,320,000-20,458,000
Earnings
Mar 31, 2025

Profile

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
URL
https://brainstorm-cell.com/
IPO date
May 28, 2003
Employees
44
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
21,439
25,107
Unusual Expense (Income)
NOPBT
(21,439)
(25,107)
NOPBT Margin
Operating Taxes
(545)
Tax Rate
NOPAT
(21,439)
(24,562)
Net income
(17,192)
-27.56%
(23,732)
-2.64%
Dividends
Dividend yield
Proceeds from repurchase of equity
18,978
238
BB yield
-10.76%
-0.03%
Debt
Debt current
1,427
Long-term debt
1,947
6,759
Deferred revenue
Other long-term liabilities
594
Net debt
647
5,203
Cash flow
Cash from operating activities
(20,458)
(19,320)
CAPEX
(18)
(29)
Cash from investing activities
2,193
998
Cash from financing activities
18,978
238
FCF
(16,582)
(19,647)
Balance
Cash
1,300
2,983
Long term investments
Excess cash
1,300
2,983
Stockholders' equity
(215,000)
(197,809)
Invested Capital
211,408
198,887
ROIC
ROCE
596.85%
EV
Common stock shares outstanding
43,076
36,509
Price
4.10
-83.35%
24.60
-59.00%
Market cap
176,396
-80.36%
898,123
-58.63%
EV
177,043
903,326
EBITDA
(21,174)
(24,822)
EV/EBITDA
Interest
545
Interest/NOPBT